M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.
Myriam Foglietta,Barbara Castella,Sara Mariani,Marta Coscia,Laura Godio,Riccardo Ferracini,Marina Ruggeri,Vittorio Emanuele Muccio,Paola Omedè,Antonio Palumbo,Mario Boccadoro,Massimo Massaia +11 more
TL;DR: The results indicate that regulatory T cells may not be the main players of immunological tolerance to myeloma cells under base-line conditions, but their fully preserved immune competence may promote their inadvertent activation and blunt T-cell driven anti-myeloma immune interventions even after myel cancer cells have successfully been cleared by chemotherapy.
Journal ArticleDOI
Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma.
Philippe Moreau,Cyrille Hulin,Thierry Facon,Mario Boccadoro,Dominique Mery-Mignard,Antoine Deslandes,Jean-Luc Harousseau +6 more
TL;DR: Ave1642 was well tolerated, except reversible grade 3 hyperglycemia observed in 2 diabetic patients, and the dose of 12 mg/kg of AVE1642 has been selected for further clinical evaluation in MM patients.
Journal ArticleDOI
Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease.
Davide Conrotto,Marco Carrozzo,Ape Valeria Ubertalli,Sergio Gandolfo,Luisa Giaccone,Mario Boccadoro,Benedetto Bruno +6 more
Journal ArticleDOI
CD38 as an immunotherapeutic target in multiple myeloma.
TL;DR: This review discusses the preclinical and clinical experience on different immunotherapeutic agents targeting CD38 in MM, allowing physicians to reach unprecedented results, especially when anti-CD38 mAbs are used in combination with consolidated MM treatments.
Journal ArticleDOI
Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM)
Marco Ladetto,Monika Brüggemann,Simone Ferrero,Francois Pepin,Daniela Drandi,Luigia Monitillo,Antonio Palumbo,Roberto Passera,Mario Boccadoro,Victoria Carlton,Heiko Trautmann,Malek Faham,Christiane Pott +12 more
TL;DR: A head to head comparison of the two methods on diagnostic (DG) and post-treatment follow-up (FU) samples on a panel of 55 patients found a significant concordance was observed and NGS is a feasible tool for IGH-based MRD monitoring in ALL, MCL and MM, in selected cases reaching similar sensitivities compared to standardized RQ-PCR.